Big In Japan: Samsung Bioepis Looks To Increase Presence With Nipro Partnership
License, Development And Commercialization Agreement Includes Ustekinumab Biosimilar
Ahead of being spun out of its parent company Samsung Biologics later this year, Samsung Bioepis has struck an agreement to bolster its presence in another Asian market and one of the largest global pharma markets.
